SUCCESSFUL COST EFFECTIVE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS USING LOW DOSE VALGANCICLOVIR

被引：1
|
作者：
Halim, Medhat [1 ]
Alotaibi, Torki [1 ]
Gheith, Osama [2 ]
Adel, Hany [1 ]
Mosaad, Ahmed [1 ]
Abo-Atteya, Hassanein [1 ]
Zakareya, Zakareya [1 ]
Said, Tarek [1 ]
Nair, Prasad [1 ]
Nampoory, Naryanan [1 ]
机构：
[1] OTC, Nephrol, Kuwait, Kuwait
[2] MUNC, Nephrol, Kuwait, Kuwait
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2015年 / 30卷
关键词：
D O I：
10.1093/ndt/gfv185.54
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FP865
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients
    Luan, F. L.
    Chopra, P.
    Park, J.
    Norman, S.
    Cibrik, D.
    Ojo, A.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (10) : 3673 - 3675
  • [22] Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir
    Nanmoku, K.
    Shinzato, T.
    Kubo, T.
    Shimizu, T.
    Kimura, T.
    Yagisawa, T.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (01) : 124 - 129
  • [23] Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation
    Avidan, Yafit Partouche
    Paul, Mical
    Rahamimov, Ruth
    Bishara, Jihad
    Samra, Zmira
    Edna, Scherf
    Mor, Eytan
    JOURNAL OF INFECTION, 2008, 57 (03) : 236 - 240
  • [24] THE EFFECT OF LOW-DOSE VS. STANDARD-DOSE VALGANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Hwang, Seon Deok
    Lee, Seoung Woo
    Kim, Moon Jae
    Song, Joon Ho
    TRANSPLANT INTERNATIONAL, 2017, 30 : 87 - 87
  • [25] EXTENDED EFFICACY OF LOW-DOSE VALGANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN INTERMEDIATE-RISK KIDNEY TRANSPLANT RECIPIENTS-TWO YEARS FOLLOW UP
    Aly, Medhat
    Gheith, Osama
    Fathi, Ahmed
    Makkeya, Yahya
    Said, Tarek
    Nair, Prasad
    Al-Otaibi, Torki
    TRANSPLANT INTERNATIONAL, 2017, 30 : 366 - 367
  • [26] A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients
    Humar, A
    Kumar, D
    Preiksaitis, J
    Boivin, G
    Siegal, D
    Fenton, J
    Jackson, K
    Nia, S
    Lien, D
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (06) : 1462 - 1468
  • [27] Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients
    Gabardi, Steven
    Asipenko, Natalya
    Fleming, James
    Lor, Kevin
    McDevitt-Potter, Lisa
    Mohammed, Anisa
    Rogers, Christin
    Tichy, Eric M.
    Weng, Renee
    Lee, Ruth-Ann
    TRANSPLANTATION, 2015, 99 (07) : 1499 - 1505
  • [28] Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis
    Gabardi, S
    Magee, CC
    Baroletti, SA
    Powelson, JA
    Cina, JL
    Chandraker, AK
    PHARMACOTHERAPY, 2004, 24 (10): : 1323 - 1330
  • [29] Valganciclovir prophylaxis for cytomegalovirus disease in kidney and simultaneous pancreas-kidney transplant recipients.
    Ciancio, G
    Burke, G
    Suzart, K
    Vaidya, A
    Roth, D
    Kupin, W
    Mattiazzi, A
    Miller, J
    JOURNAL OF UROLOGY, 2002, 167 (04): : 371 - 371
  • [30] Extended Efficacy of Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients: Two-Year Follow-Up
    Halim, Medhat A.
    Gheith, Osama A.
    Makkeya, Yahya
    Nagib, Ayman M.
    Atta, Ahmed F.
    Emam, Mohamed
    Yehia, Ahmed
    Said, Tarek
    Nair, Prasad
    Al-Otaibi, Torki
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2019, 17 (03) : 339 - 343
12345